Nature Reviews Clinical Oncology, Published online: 09 October 2025; doi:10.1038/s41571-025-01080-4
Patients with unresectable stage III non-small-cell lung cancer without EGFR or ALK mutations typically receive the PACIFIC regimen — concurrent chemoradiotherapy (cCRT) followed by consolidation with durvalumab — whereas those with EGFR-mutant disease typically receive cCRT followed by an EGFR inhibitor. Nonetheless, a subset of patients within this heterogeneous group might be able to completely avoid consolidation therapy, whereas others are unable to tolerate cCRT. In this Review, the authors describe the standard-of-care approach in this setting, followed by discussions of treatment optimization for specific subgroups, as well as important future research questions.]]>Nature Reviews Clinical Oncology, Published online: 08 October 2025; doi:10.1038/s41571-025-01074-2
Extracellular vesicles (EVs), a diverse range of membrane-delimited particles, have multiple cellular functions and, when released by cancer cells, can promote tumour growth and metastatic dissemination. The authors of this Review describe advances in the development of EVs as biomarkers and cancer therapeutics, focusing on clinical translation of EVs into diagnostic and therapeutic clinical tools.]]>Nature Reviews Clinical Oncology, Published online: 08 October 2025; doi:10.1038/s41571-025-01079-x
Epstein–Barr virus (EBV) infection has a key aetiological role in endemic nasopharyngeal carcinoma (NPC). The authors of this Review discuss advances in NPC screening, which leverage the detection of either plasma EBV DNA or serum antibodies targeting EBV antigens, as well as in prevention, which relies on prophylactic and therapeutic vaccines for NPC.]]>Nature Reviews Clinical Oncology, Published online: 03 October 2025; doi:10.1038/s41571-025-01083-1
Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care]]>Nature Reviews Clinical Oncology, Published online: 03 October 2025; doi:10.1038/s41571-025-01077-z
Patients with advanced-stage pancreatic ductal adenocarcinoma often have dismal outcomes, despite an initial response sometimes to standard-of-care chemotherapy. This treatment refractoriness partly reflects the effects of the tumour microenvironment (TME), which is highly heterogeneous but can include a dense desmoplastic stroma as well as various immune cell and cancer-associated fibroblast populations, most of which collectively promote resistance to treatment and disease progression. In this Review, the authors summarize the role of the TME in determining the outcomes of patients with pancreatic ductal adenocarcinoma, and consider novel therapeutic approaches that might promote the development of a tumour-suppressive TME.]]>Nature Reviews Clinical Oncology, Published online: 02 October 2025; doi:10.1038/s41571-025-01075-1
Chimeric antigen receptor (CAR) T cell therapy is revolutionizing the treatment of haematological malignancies, but expanding applicability to solid tumours presents substantial challenges. This Review describes key strategies to optimize CAR T cell therapy for solid tumours across areas spanning from target selection to response and safety evaluation.]]>Nature Reviews Clinical Oncology, Published online: 26 September 2025; doi:10.1038/s41571-025-01082-2
ALASCCA: an aspirin a day keeps colorectal cancer away]]>Nature Reviews Clinical Oncology, Published online: 23 September 2025; doi:10.1038/s41571-025-01081-3
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib]]>